Rezolute Shares Climb on Positive Results from Late-Stage Study of Tumor Hyperinsulinism Treatment

By Connor HartShares of Rezolute climbed after the company said its potential treatment for tumor hyperinsulinism met its primary efficacy endpoint in a recent late-stage study.The stock rose 12%, to $4.36, in premarket trading Friday. Through Thursday's close, shares are up nearly 80% year to date…